Other Consolidated Financial Statement Detail

12 Months Ended

Dec. 31, 2011

Other Consolidated Financial Statement Detail / Collaborations [Abstract]

Other Consolidated Financial Statement Detail

18.    Other Consolidated Financial Statement Detail

Supplemental Cash Flow Information

Supplemental disclosure of cash flow information for the years ended December 31, 2011, 2010 and 2009 is as follows:

	For the Years Ended December 31,
(In millions)	2011		2010		2009
Cash paid during the year for:
Interest	$	66.7	$	68.1	$	68.1
Income taxes	$	332.7	$	394.7	$	745.4

In September 2011, upon completion of our acquisition of the noncontrolling interest in our joint venture investments in Biogen Dompé SRL and Biogen Dompé Switzerland GmbH, we recorded a contingent consideration liability of $38.8 million.

In connection with the construction of the new Cambridge facilities that will be leased by us when the construction is completed, we have recorded an asset along with a corresponding financing obligation on our consolidated balance sheet as of December 31, 2011 totaling approximately $2.2 million. For additional information related to these transactions, please read Note 11, Property, Plant & Equipment to these consolidated financial statements.

In December 2010, upon completion of our acquisition of BIN, we recorded $110.9 million of in-process research and development and $25.6 million of goodwill. In addition, we also assumed a contingent consideration liability of $81.2 million and a deferred tax liability of $23.7 million.

Other Income (Expense), Net

Components of other income (expense), net, are summarized as follows:

	For the Years Ended December 31,
(In millions)	2011			2010			2009
Interest income	$	19.2		$	22.3		$	48.5
Interest expense		(33.0	)		(36.1	)		(35.8	)
Impairments on investments		(11.5	)		(21.3	)		(10.6	)
Gain (loss) on sales of investments, net		17.4			16.3			22.8
Foreign exchange gains (losses), net		(6.3	)		(3.5	)		11.4
Other, net		0.7			3.3			1.0
Total other income (expense), net	$	(13.5	)	$	(19.0	)	$	37.3

Other Current Assets

Other current assets consist of the following:

	As of December 31,
(In millions)	2011		2010
Deferred tax assets	$	8.1	$	112.2
Derivative assets		39.5		1.3
Prepaid taxes		15.2		31.4
Receivable from collaborations		11.4		7.3
Interest receivable		6.5		4.9
Other prepaid expenses		45.5		47.9
Other		18.4		10.8
Total other current assets	$	144.6	$	215.8

Accrued Expenses and Other

Accrued expenses and other consists of the following:

	As of December 31,
(In millions)	2011		2010
Employee compensation and benefits	$	176.3	$	159.7
Revenue-related rebates		115.0		105.3
Deferred revenue		69.6		41.3
Royalties and licensing fees		47.4		45.1
Collaboration expenses		44.2		31.6
Clinical development expenses		40.8		24.4
Construction in progress accrual		22.8		16.4
Interest payable		21.6		21.6
Current portion of contingent consideration		10.8		11.9
Restructuring charges		1.4		66.4
Derivative liabilities		0.5		12.2
Other		126.8		130.0
Total accrued expenses and other	$	677.2	$	665.9

For a discussion of restructuring charges accrued as of December 31, 2011 and 2010, please read Note 3, Restructuring to these consolidated financial statements.